Industry: Immunotherapy for cancer
This biopharmaceutical company is launching a pivotal phase II clinical trial with a promising new immunotherapy treatment for cancer.
PNP has developed a type of cancer immunotherapy that reprograms solid tumors to generate their own chemotherapy. The treatment works by producing PNP’s patented enzyme within the tumor, alongside inert compounds known as prodrugs. The enzyme and the inert compound interact inside the enclosed environment of the tumor, becoming pharmacologically active and releasing potent chemotherapy drugs directly into the tumor.
What makes PNP’s approach so promising is that it could offer a way to fight cancers with chemotherapy drugs currently deemed too toxic to administer directly to the sick patient. Unleashing these potent drugs within the tumor itself is more effective while minimizing side effects.
Company website: PNP Therapeutics